A031102: A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors – MALE GENDER ONLY.
A031501: Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation.
A031701: A Phase II Study of Dose‐Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle‐ Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.
EA8153: Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial.
NRG GU002: Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel .
NRG GU005: Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer.
S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG‐Naive High‐Grade Non‐ Muscle Invasive Bladder Cancer.
S1806: Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer.